Substance P induces sympathetic immune response in the contralateral eye after the first eye cataract surgery in type 2 diabetic patients

What Was Tested

Researchers studied Substance P in this randomized controlled trial publication.

Substance P (SP) is a nociceptive tachykinin which regulates the immune inflammatory reactions including monocyte chemoattractant protein 1 (MCP-1) production.

This study aims to illustrate whether SP is involved in sympathetic inflammatory responses in the contralateral eye in patients with or without type 2 diabetes.

Who Took Part

The abstract describes 51 patients taking part.

This prospective randomized clinical study included 51 cataract patients (22 with diabetes and 29 without).

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Substance P group and the comparison group should start out alike.

Bilateral sequential cataract surgeries were conducted with 1-day or 1-week interval randomly.

More than 100 μl of AH were obtained before surgery and stored for later analysis using magnetic Luminex assays to detect interleukin (IL)-1β, IL-1ra,IL-6, IL-8, IL-10, MCP-1, vascular endothelial growth factor, spinal macrophage inflammatory protein (MIP-1a), interferon-inducible protein 10 (IP-10), regulated on activation, normal T expressed and secreted (RANTES), as well as the enzyme-linked immunosorbent assay for SP.

What Was Measured

PubMed files the paper under topics including Aqueous Humor, Cataract, Cytokines, Diabetes Mellitus, Type 2, Immunity, Substance P and Vascular Endothelial Growth Factor A.

Author keywords: Inflammatory response, MCP-1 and Second-eye cataract surgery.

What This Means in Plain Language

The paper is a randomized study of Substance P in 51 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (BMC ophthalmology), a journal based in England.

More context: the Substance P compound page, all human trials.